AstraZeneca’s diabetes drug curbs heart failure, kidney risks

FILE PHOTO: A man walks past a sign at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble/File Photo

(Reuters) – The biggest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca’s Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients. However, the medicine – belonging to a class of treatments known as SGLT2 inhibitors – failed to show […]

Continue reading this article with a Fiji Times online membership.

More Stories